Trimethobenzamide HCl

A to Z Drug Facts

Trimethobenzamide HCl

	Action
	Indications
	Contraindications
	Route/Dosage
	Interactions
	Lab Test Interferences
	Adverse Reactions
	Precautions
Patient Care Considerations
	Administration/Storage
	Assessment/Interventions
	Patient/Family Education

(try-meth-oh-BEN-zuh-mide HIGH-droe-KLOR-ide)

Arrestin, T-Gen, Tebamide, Ticon, Tigan, Tiject-20, Trimazide

Class: Antiemetic and antivertigo/anticholinergic

Action Believed to directly affect medullary chemoreceptor trigger zone to inhibit nausea.

Indications Prevention and treatment of nausea and vomiting.

Contraindications Hypersensitivity to benzocaine or other local anesthetics. Suppositories contraindicated in neonates or premature infants; parenteral use contraindicated in children.

Route/Dosage

ADULTS: PO 250 mg tid-qid. PR 200 mg tid-qid. IM 200 mg tid-qid. CHILDREN 14–41 KG: PO 100–200 mg tid-qid. PR 100–200 mg tid-qid. CHILDREN < 14 KG: PR 100 mg tid-qid.

Interactions None well documented.

Lab Test Interferences None well documented.

Adverse Reactions

CV: Hypotension (after injection). CNS: Mood depression; disorientation; headache; drowsiness; opisthotonos; izziness; seizures; coma; Parkinson-like symptoms. EENT: Blurred vision. GI: Diarrhea. HEMA: Blood dyscrasias. HEPA: Jaundice. OTHER: Local pain, burning, stinging, redness and swelling (after injection); ypersensitivity reactions; muscle cramps.

Precautions

Pregnancy: Safety not established. Lactation: Undetermined. Hypersensitivity: Has been reported; discontinue use of drug at first signs of sensitivity.

PATIENT CARE CONSIDERATIONS

Administration/Storage

Do not use oral route with vomiting.
If necessary, open capsule and mix with food or liquids for administration.
Use Z-track technique for IM administration.
Avoid exposure to light; store at room temperature.
Avoid freezing injectable.

Assessment/Interventions

Obtain patient history, including drug history and any known allergies.
Assess bowel sounds and severity of nausea and vomiting.
Implement safety precautions, particularly during initial therapy until individual response is determined.
Implement general comfort measures.
Monitor response to therapy.
Monitor I&O.
Monitor vital signs, particularly BP.
Monitor for potential side effects, particularly drowsiness and hypotension.

Patient/Family Education

Instruct patient that when used for motion sickness, medication should be taken 30 min before exposure to motion.
Advise patient to report these symptoms to physician: dizziness, yellowing of skin or eyes, muscle cramps or abnormal movements.
Instruct patient to avoid intake of alcoholic beverages or other CNS depressants.
Advise patient that drug may cause drowsiness or dizziness and to use caution while driving or performing tasks requiring mental alertness.